We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IO Biotech Inc (IOBT) USD0.001

Sell:$4.50 Buy:$4.56 Change: $0.30 (6.19%)
NASDAQ:3.33%
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Sell:$4.50
Buy:$4.56
Change: $0.30 (6.19%)
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Sell:$4.50
Buy:$4.56
Change: $0.30 (6.19%)
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Contact details

Address:
Ole Maaloes Veh 3
COPENHAGEN
2200
Denmark
Telephone:
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IOBT
ISIN:
US4497781090
Market cap:
$133.13 million
Shares in issue:
28.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Mai-Britt Zocca
    President, Chief Executive Officer, Principal Financial Officer, Director
  • Brian Burkavage
    Chief Accounting Officer
  • Muhammad Al-hajj
    Chief Scientific Officer
  • Mikkel Dybkjaer
    Vice President - Corporate Finance
  • Eva Ehrnrooth
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.